Free Trial

HC Wainwright Reaffirms Neutral Rating for Zymeworks (NYSE:ZYME)

Zymeworks logo with Medical background

HC Wainwright reissued their neutral rating on shares of Zymeworks (NYSE:ZYME - Free Report) in a report published on Thursday,Benzinga reports. The brokerage currently has a $13.00 price target on the stock.

A number of other analysts have also commented on the stock. TD Cowen started coverage on shares of Zymeworks in a research note on Tuesday, May 20th. They set a "buy" rating for the company. Citigroup upped their target price on Zymeworks from $18.00 to $19.00 and gave the company a "buy" rating in a report on Friday, March 7th. Lifesci Capital started coverage on Zymeworks in a report on Tuesday, March 11th. They issued an "outperform" rating and a $30.00 target price on the stock. Finally, TD Securities started coverage on Zymeworks in a report on Tuesday, May 20th. They issued a "buy" rating on the stock. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $21.00.

Check Out Our Latest Stock Analysis on Zymeworks

Zymeworks Stock Performance

NYSE ZYME traded down $0.06 on Thursday, reaching $12.84. The company's stock had a trading volume of 285,970 shares, compared to its average volume of 583,973. Zymeworks has a twelve month low of $8.83 and a twelve month high of $17.70. The stock has a market cap of $893.02 million, a PE ratio of -8.56 and a beta of 1.19. The firm's 50 day moving average is $12.22 and its two-hundred day moving average is $12.84.

Zymeworks (NYSE:ZYME - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.15. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The company had revenue of $27.11 million during the quarter, compared to analyst estimates of $20.65 million. During the same period in the prior year, the firm earned ($0.42) earnings per share. The business's quarterly revenue was up 170.3% on a year-over-year basis. Equities research analysts anticipate that Zymeworks will post -1.39 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Ecor1 Capital, Llc acquired 73,953 shares of the company's stock in a transaction that occurred on Wednesday, April 16th. The shares were purchased at an average price of $11.16 per share, for a total transaction of $825,315.48. Following the completion of the acquisition, the director owned 17,773,727 shares of the company's stock, valued at approximately $198,354,793.32. This represents a 0.42% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders purchased a total of 129,374 shares of company stock valued at $1,460,849 in the last 90 days. Corporate insiders own 1.92% of the company's stock.

Hedge Funds Weigh In On Zymeworks

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZYME. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Zymeworks by 184.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,879,945 shares of the company's stock valued at $46,210,000 after purchasing an additional 2,514,834 shares during the last quarter. EcoR1 Capital LLC boosted its position in shares of Zymeworks by 14.8% in the first quarter. EcoR1 Capital LLC now owns 17,259,548 shares of the company's stock valued at $205,561,000 after acquiring an additional 2,231,469 shares during the period. Blackstone Inc. boosted its position in shares of Zymeworks by 2,171.4% in the fourth quarter. Blackstone Inc. now owns 569,715 shares of the company's stock valued at $8,341,000 after acquiring an additional 544,633 shares during the period. Walleye Capital LLC bought a new stake in shares of Zymeworks in the fourth quarter valued at approximately $6,629,000. Finally, Schroder Investment Management Group bought a new stake in shares of Zymeworks in the fourth quarter valued at approximately $4,892,000. Institutional investors and hedge funds own 92.89% of the company's stock.

Zymeworks Company Profile

(Get Free Report)

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.

Recommended Stories

Analyst Recommendations for Zymeworks (NYSE:ZYME)

Should You Invest $1,000 in Zymeworks Right Now?

Before you consider Zymeworks, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zymeworks wasn't on the list.

While Zymeworks currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines